Regulation of multidrug resistance by pro-inflammatory cytokines

Current Cancer Drug Targets

Volumn 6, Issue 4, 2006, Pages 295-311

  Ho, Emmanuel A ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

ABC transporters; Acute phase proteins; Acute phase response; Cytokines; Inflammation; MDR; Multidrug resistance associated protein; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; PROTEIN MRP 7; PROTEIN MRP 8; PROTEIN MRP 9; RECOMBINANT INTERLEUKIN 2; RNA POLYMERASE II; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACETYLATION; COLON CARCINOMA; DNA BINDING; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; KNOCKOUT MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY, ACTIVE; INFLAMMATION; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 33745512111     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777441753     Document Type: Review

References (170)

1. Barrand, M. A.; Bagrij, T.; Neo, S. Y. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen. Pharmacol. 1997, 28, 639-645.
2. Burt, R. K.; Poirier, M. C.; Link, C. J., Jr.; Bohr, V. A. Antineoplastic drug resistance and DNA repair. Ann. Oncol. 1991, 2, 325-334.
3. Moscow, J. A.; Townsend, A. J.; Goldsmith, M. E.; Whang-Peng, J.; Vickers, P. J.; Poisson, R.; Legault-Poisson, S.; Myers, C. E.; Cowan, K. H. Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc. Natl. Acad. Sci. USA 1988, 85, 6518-6522.
4. Gjertsen, B. T.; Logothetis, C. J.; McDonnell, T. J. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev. 1998, 17, 345-351.
5. Juranka, P. F.; Zastawny, R. L.; Ling, V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 1989, 3, 2583-2592.
6. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670.
7. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999, 59, 4237-4241.
8. Yang, C. H.; Schneider, E.; Kuo, M. L.; Volk, E. L.; Rocchi, E.; Chen, Y. C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol. 2000, 60, 831-837.
9. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
10. Borst, P.; Schinkel, A. H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 1997, 13, 217-222.
11. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
12. Kruh, G. D.; Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537-7552.
13. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
14. Steinbach, D.; Lengemann, J.; Voigt, A.; Hermann, J.; Zintl, F.; Sauerbrey, A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin. Cancer Res. 2003, 9, 1083-1086.
15. Tada, Y.; Wada, M.; Migita, T.; Nagayama, J.; Hinoshita, E.; Mochida, Y.; Maehara, Y.; Tsuneyoshi, M.; Kuwano, M.; Naito, S. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int. J. Cancer 2002, 98, 630-635.
16. Nies, A. T.; Konig, J.; Pfannschmidt, M.; Klar, E.; Hofmann, W. J.; Keppler, D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 2001, 94, 492-499.
17. Ohno, N.; Tani, A.; Chen, Z. S.; Uozumi, K.; Hanada, S.; Akiba, S.; Ren, X. Q.; Furukawa, T.; Sumizawa, T.; Arima, T.; Akiyama, S. I. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin. Cancer Res. 2001, 7, 3120-3126.
18. Rudas, M.; Filipits, M.; Taucher, S.; Stranzl, T.; Steger, G. G.; Jakesz, R.; Pirker, R.; Pohl, G. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res. Treat 2003, 81, 149-157.
19. Xiang, R.; Mizutani, N.; Luo, Y.; Chiodoni, C.; Zhou, H.; Mizutani, M.; Ba, Y.; Becker, J. C.; Reisfeld, R. A. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65, 553-561.
20. Stokkers, P. C.; Hommes, D. W. New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004, 28, 167-173.
21. Mannon, P. J.; Fuss, I. J.; Mayer, L.; Elson, C. O.; Sandborn, W. J.; Present, D.; Dolin, B.; Goodman, N.; Groden, C.; Hornung, R. L.; Quezado, M.; Neurath, M. F.; Salfeld, J.; Veldman, G. M.; Schwertschlag, U.; Strober, W. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 2004, 351, 2069-2079.
22. Morgan, E. T. Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin. Mol. Pharmacol. 1989, 36, 699-707.
23. Kalitsky-Szirtes, J.; Shayeganpour, A.; Brocks, D. R.; Piquette-Miller, M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos. 2004, 32, 20-27.
24. Ghezzi, P.; Saccardo, B.; Villa, P.; Rossi, V.; Bianchi, M.; Dinarello, C. A. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect. Immun. 1986, 54, 837-840.
25. Dirckx, J. H. Inflammation. In Stedman's Concise Medical Dictionary for the Health Professions; Balitmore: Lippincott Williams & Wilkins, 2001.
26. Berczi, I.; Chow, D. A.; Sabbadini, E. R. Neuroimmunoregulation and natural immunity. Domest. Anim. Endocrinol. 1998, 15, 273-281.
27. Kolb-Bachofen, V. A review on the biological properties of C-reactive protein. Immunobiology 1991, 183, 133-145.
28. Baker, D. G.; Rabinowitz, J. L. Current concepts in the treatment of rheumatoid arthritis. J. Clin. Pharmacol. 1986, 26, 2-21.
29. Bingham, C. O., 3rd. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J. Rheumatol.(Suppl.) 2002, 65, 3-9.
30. Llorente, L.; Richaud-Patin, Y.; Diaz-Borjon, A.; Alvarado de la Barrera, C.; Jakez-Ocampo, J.; de la Fuente, H.; Gonzalez-Amaro, R.; Diaz-Jouanen, E. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000, 67, 30-39.
31. Bornstein, D. L. Leukocytic pyrogen: a major mediator of the acute phase reaction. Ann. N. Y. Acad. Sci. 1982, 389, 323-337.
32. Dinarello, C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N. Engl. J. Med. 1984, 311, 1413-1418.
33. Zahedi, K.; Whitehead, A. S. Regulation of mouse serum amyloid P gene expression by cytokines in vitro. Biochim. Biophys. Acta 1993, 1176, 162-168.
34. Ku, N. O.; Mortensen, R. F. The mouse C-reactive protein (CRP) gene is expressed in response to IL-1 but not IL-6. Cytokine 1993, 5, 319-326.
35. Blasi, F.; Riccio, M.; Brogi, A.; Strazza, M.; Taddei, M. L.; Romagnoli, S.; Luddi, A.; D'Angelo, R.; Santi, S.; Costantino-Ceccarini, E.; Melli, M. Constitutive expression of interleukin-1beta (IL-1beta) in rat oligodendrocytes. Biol. Chem. 1999, 380, 259-264.
36. Quan, N.; Zhang, Z.; Emery, M.; Bonsall, R.; Weiss, J. M. Detection of interleukin-1 bioactivity in various brain regions of normal healthy rats. Neuroimmunomodulation 1996, 3, 47-55.
37. Seymour, J. F.; K. R. In Cytokines: interleukins and their receptors; Norwell, MA: Kluwer Academic Publishers, 1995.
38. Dinarello, C. A. An update on human interleukin-1: from molecular biology to clinical relevance. J. Clin. Immunol. 1985, 5, 287-297.
39. Fantuzzi, G.; Dinarello, C. A. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J. Leukoc. Biol. 1996, 59, 489-493.
40. Alvaro-Gracia, J. M.; Zvaifler, N. J.; Brown, C. B.; Kaushansky, K.; Firestein, G. S. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J. Immunol. 1991, 146, 3365-3371.
41. Paulusma, C. C.; Kool, M.; Bosma, P. J.; Scheffer, G. L.; ter Borg, F.; Scheper, R. J.; Tytgat, G. N.; Borst, P.; Baas, F.; Oude Elferink, R. P. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997, 25, 1539-1542.
42. Piquette-Miller, M.; Pak, A.; Kim, H.; Anari, R.; Shahzamani, A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res. 1998, 15, 706-711.
43. Hirohashi, T.; Suzuki, H.; Ito, K.; Ogawa, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol. Pharmacol. 1998, 53, 1068-1075.
44. Bell, D. R.; Gerlach, J. H.; Kartner, N.; Buick, R. N.; Ling, V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol. 1985, 3, 311-315.
45. Panwala, C. M.; Jones, J. C.; Viney, J. L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J . Immunol. 1998, 161, 5733-5744.
46. Bristow, A. F.; Mosley, K.; Poole, S. Interleukin-1 beta production in vivo and in vitro in rats and mice measured using specific immunoradiometric assays. J. Mol. Endocrinol. 1991, 7, 1-7.
47. Andersson, J.; Nagy, S.; Bjork, L.; Abrams, J.; Holm, S.; Andersson, U. Bacterial toxin-induced cytokine production studied at the single-cell level. Immunol. Rev. 1992, 127, 69-96.
48. Ertel, W.; Morrison, M. H.; Wang, P.; Ba, Z. F.; Ayala, A.; Chaudry, I. H. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann. Surg. 1991, 214, 141-148.
49. Fattori, E.; Cappelletti, M.; Costa, P.; Sellitto, C.; Cantoni, L.; Carelli, M.; Faggioni, R.; Fantuzzi, G.; Ghezzi, P.; Poli, V. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 1994, 180, 1243-1250.
50. Morgan, E. T. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 1997, 29, 1129-1188.
51. Tang, W.; Yi, C.; Kalitsky, J.; Piquette-Miller, M. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol. Cell Biol. Res. Commun. 2000, 4, 90-97.
52. Sukhai, M.; Yong, A.; Pak, A.; Piquette-Miller, M. Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm. Res. 2001, 50, 362-370.
53. Lee, G.; Piquette-Miller, M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can. J. Physiol. Pharmacol. 2001, 79, 876-884.
54. Sukhai, M.; Yong, A.; Kalitsky, J.; Piquette-Miller, M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b Genes. Mol. Cell Biol. Res. Commun. 2000, 4, 248-256.
55. Cherrington, N. J.; Slitt, A. L.; Li, N.; Klaassen, C. D. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 2004, 32, 734-741.
56. Miyoshi, M.; Nadai, M.; Nitta, A.; Ueyama, J.; Shimizu, A.; Takagi, K.; Nabeshima, T.; Saito, K.; Hasegawa, T. Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin. Eur. J. Pharmacol. 2005, 507, 229-237.
57. Bonhomme-Faivre, L.; Pelloquin, A.; Tardivel, S.; Urien, S.; Mathieu, M. C.; Castagne, V.; Lacour, B.; Farinotti, R. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer Drugs 2002, 13, 51-57.
58. Castagne, V.; Bonhomme-Faivre, L.; Urien, S.; Reguiga, M. B.; Soursac, M.; Gimenez, F.; Farinotti, R. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Drug Metab. Dispos. 2004, 32, 168-171.
59. Dumoulin, F. L.; Reichel, C.; Sauerbruch, T.; Spengler, U. Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. J. Hepatol. 1997, 26, 852-856.
60. Mahmoud, F. A.; Rivera, N. I. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr. Oncol. Rep. 2002, 4, 250-255.
61. Slaviero, K. A.; Clarke, S. J.; Rivory, L. P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003, 4, 224-232.
62. Vener, C.; Guffanti, A.; Pomati, M.; Colombi, M.; Alietti, A.; La Targia, M. L.; Bamonti-Catena, F.; Baldini, L. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk. Lymphoma 2000, 37, 333-339.
63. Ashizawa, T.; Okada, R.; Suzuki, Y.; Takagi, M.; Yamazaki, T.; Sumi, T.; Aoki, T.; Ohnuma, S. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005, 8, 124-131.
64. Schumann, R. R.; Leong, S. R.; Flaggs, G. W.; Gray, P. W.; Wright, S. D.; Mathison, J. C.; Tobias, P. S.; Ulevitch, R. J. Structure and function of lipopolysaccharide binding protein. Science 1990, 249, 1429-1431.
65. Ulevitch, R. J.; Tobias, P. S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann. Rev. Immunol. 1995, 13, 437-457.
66. Alexander, C.; Rietschel, E. T. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 2001, 7, 167-202.
67. Baumann, H.; Richards, C.; Gauldie, J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J. Immunol. 1987, 139, 4122-4128.
68. Ceciliani, F.; Giordano, A.; Spagnolo, V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept. Lett. 2002, 9, 211-223.
69. Ardies, C. M. Inflammation as cause for scar cancers of the lung. Integr. Cancer Ther. 2003, 2, 238-246.
70. Moldawer, L. L.; Gelin, J.; Schersten, T.; Lundholm, K. G. Circulating interleukin 1 and tumor necrosis factor during inflammation. Am. J. Physiol. 1987, 253, R922-R928.
71. Takeuchi, O.; Akira, S. Toll-like receptors; their physiological role and signal transduction system. Int. Immunopharmacol. 2001, 1, 625-635.
72. Moshage, H. Cytokines and the hepatic acute phase response. J. Pathol. 1997, 181, 257-266.
73. Gerard, N.; Caillaud, M.; Martoriati, A.; Goudet, G.; Lalmanach, A. C. The interleukin-1 system and female reproduction. J. Endocrinol. 2004, 180, 203-212.
74. Gaur, U.; Aggarwal, B. B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 2003, 66, 1403-1408.
75. Kamimura, D.; Ishihara, K.; Hirano, T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149, 1-38.
76. Agrawal, A.; Cha-Molstad, H.; Samols, D.; Kushner, I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 2003, 108, 539-547.
77. Betts, J. C.; Cheshire, J. K.; Akira, S.; Kishimoto, T.; Woo, P. The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J. Biol. Chem. 1993, 268, 25624-25631.
78. Buck, M.; Zhang, L.; Halasz, N. A.; Hunter, T.; Chojkier, M. Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha. EMBO J. 2001, 20, 6712-6723.
79. Akira, S.; Kishimoto, T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 1992, 127, 25-50.
80. Levy, D. E.; Lee, C. K. What does Stat3 do? J. Clin. Invest. 2002, 109, 1143-1148.
81. Ramji, D. P.; Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 2002, 365, 561-575.
82. Stein, B.; Cogswell, P. C.; Baldwin, A. S., Jr. Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol. Cell Biol. 1993, 13, 3964-3974.
83. Yu, L.; Wu, Q.; Yang, C. P.; Horwitz, S. B. Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the mdr1b promoter. Cell Growth Differ. 1995, 6, 1505-1512.
84. Zahnow, C. A.; Younes, P.; Laucirica, R.; Rosen, J. M. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J. Natl. Cancer Inst. 1997, 89, 1887-1891.
85. Ihle, J. N. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 2001, 13, 211-217.
86. Seidel, H. M.; Milocco, L. H.; Lamb, P.; Darnell, J. E., Jr.; Stein, R. B.; Rosen, J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 1995, 92, 3041-3045.
87. Sherman, C. T.; Brasier, A. R. Role of signal transducers and activators of transcription 1 and -3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol. Endocrinol. 2001, 15, 441-457.
88. Kordula, T.; Rydel, R. E.; Brigham, E. F.; Horn, F.; Heinrich, P. C.; Travis, J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes. J Biol. Chem. 1998, 273, 4112-4118.
89. Wegenka, U. M.; Buschmann, J.; Lutticken, C.; Heinrich, P. C.; Horn, F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol. Cell Biol. 1993, 13, 276-288.
90. Combates, N. J.; Rzepka, R. W.; Chen, Y. N.; Cohen, D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol. Chem. 1994, 269, 29715-29719.
91. Dreuw, A.; Hermanns, H. M.; Heise, R.; Joussen, S.; Rodriguez, F.; Marquardt, Y.; Jugert, F.; Merk, H. F.; Heinrich, P. C.; Baron, J. M. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J. Invest. Dermatol. 2005, 124, 28-37.
92. Smale, S. T. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1997, 1351, 73-88.
93. Grant, C. E.; Kurz, E. U.; Cole, S. P.; Deeley, R. G. Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 1997, 45, 368-378.
94. Cornwell, M. M. The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ. 1990, 1, 607-615.
95. Poli, V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J. Biol. Chem. 1998, 273, 29279-29282.
96. Kliewer, S. A.; Moore, J. T.; Wade, L.; Staudinger, J. L.; Watson, M. A.; Jones, S. A.; McKee, D. D.; Oliver, B. B.; Willson, T. M.; Zetterstrom, R. H.; Perlmann, T.; Lehmann, J. M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92, 73-82.
97. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA 1998, 95, 12208-12213.
98. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276, 14581-14587.
99. Kast, H. R.; Goodwin, B.; Tarr, P. T.; Jones, S. A.; Anisfeld, A. M.; Stoltz, C. M.; Tontonoz, P.; Kliewer, S.; Willson, T. M.; Edwards, P. A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277, 2908-2915.
100. Teng, S.; Jekerle, V.; Piquette-Miller, M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 2003, 31, 1296-1299.
101. Pascussi, J. M.; Gerbal-Chaloin, S.; Pichard-Garcia, L.; Daujat, M.; Fabre, J. M.; Maurel, P.; Vilarem, M. J. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Biophys. Res. Commun. 2000, 274, 707-713.
102. Beigneux, A. P.; Moser, A. H.; Shigenaga, J. K.; Grunfeld, C.; Feingold, K. R. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 2002, 293, 145-149.
103. Teng, S.; Piquette-Miller, M. The Involvement of the Pregnane X Receptor in Hepatic Gene Regulation during Inflammation in Mice. J. Pharmacol. Exp. Ther. 2005, 312, 841-848.
104. Kim, M. S.; Shigenaga, J.; Moser, A.; Grunfeld, C.; Feingold, K. R. Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 2004, 287, E731-E738.
105. Flynn, V., Jr.; Ramanitharan, A.; Moparty, K.; Davis, R.; Sikka, S.; Agrawal, K. C.; Abdel-Mageed, A. B. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int. J. Oncol. 2003, 23, 317-323.
106. Walther, W.; Stein, U.; Fichtner, I.; Alexander, M.; Shoemaker, R. H.; Schlag, P. M. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther. 2000, 7, 893-900.
107. Beerli, R. R.; Dreier, B.; Barbas, C. F., 3rd. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 2000, 97, 1495-1500.
108. Kang, J. S.; Kim, J. S. Zinc finger proteins as designer transcription factors. J Biol. Chem. 2000, 275, 8742-8748.
109. Bae, C. D.; Juhnn, Y. S.; Park, J. B. Post-transcriptional control of c-erb B-2 overexpression in stomach cancer cells. Exp. Mol. Med. 2001, 33, 15-19.
110. Wang, Y.; Dang, J.; Liang, X.; Doe, W. F. Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin. Exp. Metastasis 1995, 13, 196-202.
111. Albertioni, F.; Gruber, A.; Arestrom, I.; Vitols, S. Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Med. Oncol. 1995, 12, 79-86.
112. Lee, C. H. Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated. Mol. Cell Biochem. 2001, 216, 103-110.
113. Lee, C. H.; Bradley, G.; Ling, V. Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ. 1995, 6, 347-354.
114. Lee, C. H.; Bradley, G.; Ling, V. Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo. J. Cell Physiol. 1998, 177, 1-12.
115. Piechaczyk, M.; Yang, J. Q.; Blanchard, J. M.; Jeanteur, P.; Marcu, K. B. Posttranscriptional mechanisms are responsible for accumulation of truncated c-myc RNAs in murine plasma cell tumors. Cell 1985, 42, 589-597.
116. Rabbitts, P. H.; Forster, A.; Stinson, M. A.; Rabbitts, T. H. Truncation of exon 1 from the c-myc gene results in prolonged c-myc mRNa stability. EMBO J. 1985, 4, 3727-3733.
117. Sidransky, H.; Murty, C. N.; Verney, E. Turnover of messenger RNA in transplantable hepatomas and host liver of rats. Cancer Res. 1978, 38, 1645-1653.
118. Laurencot, C. M.; Scheffer, G. L.; Scheper, R. J.; Shoemaker, R. H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer 1997, 72, 1021-1026.
119. Molinari, A.; Calcabrini, A.; Meschini, S.; Stringaro, A.; Del Bufalo, D.; Cianfriglia, M.; Arancia, G. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int. J. Cancer 1998, 75, 885-893.
120. Fine, R. L.; Chambers, T. C.; Sachs, C. W. P-Glycoprotein, Multidrug Resistance and Protein Kinase C. Oncologist 1996, 1, 261-268.
121. Abeijon, C.; Mandon, E. C.; Hirschberg, C. B. Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus. Trends Biochem. Sci. 1997, 22, 203-207.
122. McClean, S.; Hill, B. T. Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur. J. Cancer 1993, 29A, 2243-2248.
123. Muller, C.; Laurent, G.; Ling, V. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J. Cell Physiol. 1995, 163, 538-544.
124. Zhang, W.; Ling, V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J. Cell Physiol. 2000, 184, 17-26.
125. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A.; van Deemter, L.; Smit, J. J.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 1997, 94, 4028-4033.
126. Wijnholds, J.; Evers, R.; van Leusden, M. R.; Mol, C. A.; Zaman, G. J.; Mayer, U.; Beijnen, J. H.; van der Valk, M.; Krimpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 1997, 3, 1275-1279.
127. Cascorbi, I.; Gerloff, T.; Johne, A.; Meisel, C.; Hoffmeyer, S.; Schwab, M.; Schaeffeler, E.; Eichelbaum, M.; Brinkmann, U.; Roots, I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001, 69, 169-174.
128. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 3473-3478.
129. Sakaeda, T.; Nakamura, T.; Okumura, K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 2002, 25, 1391-1400.
130. Jamroziak, K.; Mlynarski, W.; Balcerczak, E.; Mistygacz, M.; Trelinska, J.; Mirowski, M.; Bodalski, J.; Robak, T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 2004, 72, 314-321.
131. Plasschaert, S. L.; Groninger, E.; Boezen, M.; Kema, I.; de Vries, E. G.; Uges, D.; Veerman, A. J.; Kamps, W. A.; Vellenga, E.; de Graaf, S. S.; de Bont, E. S. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 2004, 76, 220-229.
132. Meissner, K.; Jedlitschky, G.; Meyer zu Schwabedissen, H.; Dazert, P.; Eckel, L.; Vogelgesang, S.; Warzok, R. W.; Bohm, M.; Lehmann, C.; Wendt, M.; Cascorbi, I.; Kroemer, H. K. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004, 14, 381-385.
133. Pawlik, A.; Wrzesniewska, J.; Fiedorowicz-Fabrycy, I.; Gawronska-Szklarz, B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 2004, 42, 496-503.
134. Bertilsson, P. M.; Olsson, P.; Magnusson, K. E. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J. Pharm. Sci. 2001, 90, 638-646.
135. Lindell, M.; Karlsson, M. O.; Lennernas, H.; Pahlman, L.; Lang, M. A. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Invest. 2003, 33, 493-499.
136. Runge, D.; Kohler, C.; Kostrubsky, V. E.; Jager, D.; Lehmann, T.; Runge, D. M.; May, U.; Stolz, D. B.; Strom, S. C.; Fleig, W. E.; Michalopoulos, G. K. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem. Biophys. Res. Commun. 2000, 273, 333-341.
137. Schuetz, E. G.; Schuetz, J. D.; Thompson, M. T.; Fisher, R. A.; Madariage, J. R.; Strom, S. C. Phenotypic variability in induction of P-glycoprotein mRNA by aromatic hydrocarbons in primary human hepatocytes. Mol. Carcinog. 1995, 12, 61-65.
138. Schuetz, E. G.; Umbenhauer, D. R.; Yasuda, K.; Brimer, C.; Nguyen, L.; Relling, M. V.; Schuetz, J. D.; Schinkel, A. H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol. 2000, 57, 188-197.
139. Schuetz, E. G.; Schinkel, A. H.; Relling, M. V.; Schuetz, J. D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 1996, 93, 4001-4005.
140. Lee, S. S.; Buters, J. T.; Pineau, T.; Fernandez-Salguero, P.; Gonzalez, F. J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 1996, 271, 12063-12067.
141. Liang, H. C.; Li, H.; McKinnon, R. A.; Duffy, J. J.; Potter, S. S.; Puga, A.; Nebert, D. W. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc. Natl. Acad. Sci. USA 1996, 93, 1671-1676.
142. Huang, L.; Wring, S. A.; Woolley, J. L.; Brouwer, K. R.; Serabjit-Singh, C.; Polli, J. W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 2001, 29, 754-760.
143. Kusaba, H.; Nakayama, M.; Harada, T.; Nomoto, M.; Kohno, K.; Kuwano, M.; Wada, M. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur. J. Biochem. 1999, 262, 924-932.
144. Tada, Y.; Wada, M.; Kuroiwa, K.; Kinugawa, N.; Harada, T.; Nagayama, J.; Nakagawa, M.; Naito, S.; Kuwano, M. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin. Cancer Res. 2000, 6, 4618-4627.
145. Stein, U.; Walther, W.; Shoemaker, R. H. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br. J. Cancer 1996, 74, 1384-1391.
146. Veau, C.; Faivre, L.; Tardivel, S.; Soursac, M.; Banide, H.; Lacour, B.; Farinotti, R. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J. Pharmacol. Exp. Ther. 2002, 302, 742-750.
147. Johnson, B. J.; Ress, S. R.; Willcox, P.; Pati, B. P.; Lorgat, F.; Stead, P.; Saha, R.; Lukey, P.; Laochumroonvorapong, P.; Corral, L.; et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol. Ther. 1995, 1, 185-196.
148. Johnson, B. J.; Estrada, I.; Shen, Z.; Ress, S.; Willcox, P.; Colston, M. J.; Kaplan, G. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect. Immun. 1998, 66, 2426-2433.
149. Niethammer, A. G.; Wodrich, H.; Loeffler, M.; Lode, H. N.; Emmerich, K.; Abdollahi, A.; Krempien, R.; Debus, J.; Huber, P. E.; Reisfeld, R. A. Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J. 2005, 19, 158-159.
150. Shtil, A. A.; Turner, J. G.; Durfee, J.; Dalton, W. S.; Yu, H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 1999, 93, 1831-1837.
151. de Jong, M. C.; Scheffer, G. L.; Broxterman, H. J.; Hooijberg, J. H.; Slootstra, J. W.; Meloen, R. H.; Kreitman, R. J.; Husain, S. R.; Joshi, B. H.; Puri, R. K.; Scheper, R. J. Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1. Clin. Cancer Res. 2003, 9, 5009-5017.
152. Husain, S. R.; Kreitman, R. J.; Pastan, I.; Puri, R. K. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat. Med. 1999, 5, 817-822.
153. Manara, M. C.; Serra, M.; Benini, S.; Picci, P.; Scotlandi, K. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int. J. Oncol. 2004, 24, 365-372.
154. Raguse, J. D.; Gath, H. J.; Oettle, H.; Bier, J. Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int. J. Oral Maxillofac. Surg. 2004, 33, 606-609.
155. Kartner, N.; Riordan, J. R.; Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221, 1285-1288.
156. Van der Bliek, A. M.; Baas, F.; Ten Houte de Lange, T.; Kooiman, P. M.; Van der Velde-Koerts, T.; Borst, P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J. 1987, 6, 3325-3331.
157. Schinkel, A. H.; Roelofs, E. M.; Borst, P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res. 1991, 51, 2628-2635.
158. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
159. Paulusma, C. C.; Bosma, P. J.; Zaman, G. J.; Bakker, C. T.; Otter, M.; Scheffer, G. L.; Scheper, R. J.; Borst, P.; Oude Elferink, R. P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271, 1126-1128.
160. Kiuchi, Y.; Suzuki, H.; Hirohashi, T.; Tyson, C. A.; Sugiyama, Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998, 433, 149-152.
161. Kool, M.; de Haas, M.; Scheffer, G. L.; Scheper, R. J.; van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
162. Wijnholds, J.; Mol, C. A.; van Deemter, L.; de Haas, M.; Scheffer, G. L.; Baas, F.; Beijnen, J. H.; Scheper, R. J.; Hatse, S.; De Clercq, E.; Balzarini, J.; Borst, P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 2000, 97, 7476-7481.
163. Kool, M.; van der Linden, M.; de Haas, M.; Baas, F.; Borst, P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999, 59, 175-182.
164. Kao, H. H.; Huang, J. D.; Chang, M. S. cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene 2002, 286, 299-306.
165. Chen, Z. S.; Hopper-Borge, E.; Belinsky, M. G.; Shchaveleva, I.; Kotova, E.; Kruh, G. D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 2003, 63, 351-358.
166. Bera, T. K.; Lee, S.; Salvatore, G.; Lee, B.; Pastan, I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. 2001, 7, 509-516.
167. Pastor-Anglada, M.; Molina-Arcas, M.; Casado, F. J.; Bellosillo, B.; Colomer, D.; Gil, J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004, 18, 385-393.
168. Bera, T. K.; Iavarone, C.; Kumar, V.; Lee, S.; Lee, B.; Pastan, I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. USA 2002, 99, 6997-7002.
169. Childs, S.; Yeh, R. L.; Georges, E.; Ling, V. Identification of a sister gene to P-glycoprotein. Cancer Res. 1995, 55, 2029-2034.
170. Green, R. M.; Hoda, F.; Ward, K. L. Molecular cloning and characterization of the murine bile salt export pump. Gene 2000, 241, 117-123.